图书简介

Preface ; Chapter 1: Discovery and Chemical Development of the Use-Dependent Sodium Channel Blocker Vixotrigine for the Treatment of Pain, David R. Witty, David T. MacPherson, Gerard M. P. Giblin, Michael T. Williams, Robbie Chen, Vinny Couming, John Guzowski, Erwin Irdam, William F. Kiesman, Daw-Iong Albert Kwok, Wenli Liang, Tamera L. Mack, Erin M. O’Brien, Suzanne M. Opalka, Daniel Patience, Stefan Sahli, Donald G. Walker, and Frederick Osei-Yeboah; Chapter 2: The Discovery and Chemical Development of BMS-919373: A Selective IKur Inhibitor for the Potential Treatment of Atrial Fibrillation, Heather J. Finlay, Scott A. Savage, Jason M. Stevens, Steven R. Wisniewski, and Miao Yu; Chapter 3: Discovery and Development of Omecamtiv Mecarbil: A Novel Cardiac Myosin Activator for the Potential Treatment of Systolic Heart Failure, Bradley P. Morgan, Seb Caille, and Shawn D. Walker; Chapter 4: Identification and Development of AMG 986: A Potent and Efficacious APJ Agonist for the Treatment of Heart Failure, Matthew R. Kaller, Paul Dransfield, Robert P. Farrell, and Ted C. Judd; Chapter 5: Melflufen: A Journey from Discovery to Multi-Kilogram Production, Fredrik Lehmann and Johan Wennerberg; Chapter 6: Discovery and Chemical Development of S 44563, a Dual Bcl-2/Bcl-xL Inhibitor, Christophe Hardouin and Jerome-Benoit Starck; Chapter 7: Discovery and Chemical Development of Tesirine: An Antitumor Pyrrolobenzodiazepine Antibody-Drug Conjugate Drug-Linker, Arnaud C. Tiberghien and Jeremy S. Parker; Chapter 8: Discovery and Chemical Development of Relebactam: A Potent Beta-Lactamase Inhibitor in Combination with PrimaxinR for the Treatment of Serious and Antibiotic-Resistant Bacterial Infections, Feng Xu, Benjamin D. Sherry, and Timothy A. Blizzard; Chapter 9: Discovery and Chemical Development of Grazoprevir: An HCV NS3/4a Protease Inhibitor for the Treatment of the Hepatitis C Virus Infection, Feng Xu and John A. McCauley; Chapter 10: Discovery and Process Development of BIIB068: A Reversible Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Autoimmune Diseases, Bin Ma, Chaomin Li, Brian T. Hopkins, Lloyd Franklin, Robbie Chen, Tamera Mack, Daniel Patience, William F. Kiesman, and Erin M. O’Brien; Chapter 11: Discovery and Commercial Development of Cholesteryl Transfer Protein Inhibitor Evacetrapib, Nathan B. Mantlo and Scott A. Frank; Editor’s Biographies; Author Index; Subject Index

Trade Policy 买家须知